First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial

作者：Hua Zhong, Shengjie Sun, Jianhua Chen, Ziping Wang, Yanqiu Zhao, Guojun Zhang, Gongyan Chen, Ming Zhou, Jianying Zhou, Yingying Du, Lin Wu, Zhi Xu, Xiaodong Mei, Weidong Zhang, Jingdong He, Jiuwei Cui, Zhihong Zhang, Hui Luo, Weiyou Liu, Meili Sun, Jingxun Wu, Yongchun Shen, Shucai Zhang, Nong Yang, Mengzhao Wang, Junguo Lu, Kai Li, Weirong Yao, Qian Sun, Hongmei Yue, Lin Wang, Sheng Ye, Bin Li, Xibin Zhuang, Yueyin Pan, Min Zhang, Yongqian Shu, Zhiyong He, Lei Pan, L. Yang, Shengming Liu, Qi Zhang, Shunchang Jiao, Baohui Han · 发表于：The Lancet Respiratory Medicine · 年份：2024 · DOI：10.1016/s2213-2600(23)00431-9 · 被引用次数：58 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Peptidase Inhibition and Analysis